In Setback for Glaxo, U.K. Invalidates Paxil Patent
The Lords ruled in late October that Glaxo’s patent for the compound paroxetine mesylate was invalid and upheld an appeal brought by challenger Synthon against the decision of the Court of Appeal, which was made in June 2003. Paroxetine mesylate incorporates the main ingredient of Paxil, one of Glaxo’s best selling drugs.
Synthon challenged the validity...
To view the full article, register now.